Association of Sarcopenia with a Poor Prognosis and Decreased Tumor-Infiltrating CD8-Positive T Cells in Pancreatic Ductal Adenocarcinoma: A Retrospective Analysis.
Sarcopenia
/ diagnostic imaging
Prognosis
Carcinoma, Pancreatic Ductal
/ complications
Pancreatic Neoplasms
/ complications
Lymphocytes, Tumor-Infiltrating
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
Neoplasm Staging
Humans
Male
Female
Adult
Middle Aged
Aged
Aged, 80 and over
Muscle, Skeletal
/ diagnostic imaging
Immune cells
Pancreatic ductal adenocarcinoma
Sarcopenia
Skeletal muscle index
Tumor microenvironment
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
11
11
2022
accepted:
27
02
2023
medline:
11
8
2023
pubmed:
16
5
2023
entrez:
16
5
2023
Statut:
ppublish
Résumé
Sarcopenia, defined as a loss of skeletal muscle mass and quality, is found in 30-65% of patients with pancreatic ductal adenocarcinoma (PDAC) at diagnosis, and is a poor prognostic factor. However, it is yet to be evaluated why sarcopenia is associated with poor prognosis. Therefore, this study elucidated the tumor characteristics of PDAC with sarcopenia, including driver gene alterations and tumor microenvironment. We retrospectively analyzed 162 patients with PDAC who underwent pancreatic surgery between 2008 and 2017. We defined sarcopenia by measuring the skeletal muscle mass at the L3 level using preoperative computed tomography images and evaluated driver gene alteration (KRAS, TP53, CDKN2A/p16, and SMAD4) and tumor immune (CD4 In localized-stage PDAC (stage ≤ IIa), overall survival (OS) and recurrence-free survival were significantly shorter in the sarcopenia group than in the non-sarcopenia group (2-year OS 89.7% versus 59.1%, P = 0.03; 2-year RFS 74.9% versus 50.0%, P = 0.02). Multivariate analysis revealed that sarcopenia was an independent poor prognostic factor in localized-stage PDAC. Additionally, tumor-infiltrating CD8 Sarcopenia was associated with a worse prognosis and decreased tumor-infiltrating CD8
Sections du résumé
BACKGROUND
BACKGROUND
Sarcopenia, defined as a loss of skeletal muscle mass and quality, is found in 30-65% of patients with pancreatic ductal adenocarcinoma (PDAC) at diagnosis, and is a poor prognostic factor. However, it is yet to be evaluated why sarcopenia is associated with poor prognosis. Therefore, this study elucidated the tumor characteristics of PDAC with sarcopenia, including driver gene alterations and tumor microenvironment.
PATIENTS AND METHODS
METHODS
We retrospectively analyzed 162 patients with PDAC who underwent pancreatic surgery between 2008 and 2017. We defined sarcopenia by measuring the skeletal muscle mass at the L3 level using preoperative computed tomography images and evaluated driver gene alteration (KRAS, TP53, CDKN2A/p16, and SMAD4) and tumor immune (CD4
RESULTS
RESULTS
In localized-stage PDAC (stage ≤ IIa), overall survival (OS) and recurrence-free survival were significantly shorter in the sarcopenia group than in the non-sarcopenia group (2-year OS 89.7% versus 59.1%, P = 0.03; 2-year RFS 74.9% versus 50.0%, P = 0.02). Multivariate analysis revealed that sarcopenia was an independent poor prognostic factor in localized-stage PDAC. Additionally, tumor-infiltrating CD8
CONCLUSIONS
CONCLUSIONS
Sarcopenia was associated with a worse prognosis and decreased tumor-infiltrating CD8
Identifiants
pubmed: 37191859
doi: 10.1245/s10434-023-13569-2
pii: 10.1245/s10434-023-13569-2
pmc: PMC10409680
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5776-5787Subventions
Organisme : Japan Society for the Promotion of Science
ID : 19K08444
Organisme : Japan Society for the Promotion of Science
ID : 22H03058
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023. The Author(s).
Références
Ann Surg Oncol. 2022 Aug;29(8):4924-4934
pubmed: 35606470
J Gastrointest Surg. 2012 Aug;16(8):1478-86
pubmed: 22692586
Br J Surg. 2016 Mar;103(4):434-42
pubmed: 26780231
Int J Surg. 2017 Mar;39:45-51
pubmed: 28110029
Appl Physiol Nutr Metab. 2008 Oct;33(5):997-1006
pubmed: 18923576
Surgery. 2017 Mar;161(3):584-591
pubmed: 28040257
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
J Gastrointest Surg. 2015 Sep;19(9):1593-602
pubmed: 25925237
J Gastrointest Surg. 2018 May;22(5):831-839
pubmed: 29392613
Physiol Rev. 2008 Oct;88(4):1379-406
pubmed: 18923185
Cancer Lett. 2020 Aug 1;484:29-39
pubmed: 32344015
Aging (Albany NY). 2012 Aug;4(8):535-46
pubmed: 22935594
J Gastrointest Surg. 2016 Sep;20(9):1586-94
pubmed: 27126054
Lancet. 2016 Jul 16;388(10041):248-57
pubmed: 27265347
Int J Surg. 2018 Nov;59:19-26
pubmed: 30266663
Science. 2022 Jan 07;375(6576):eabf9419
pubmed: 34990248
Front Physiol. 2014 Mar 03;5:88
pubmed: 24624094
Pancreatology. 2018 Dec;18(8):996-1004
pubmed: 30287167
Hepatol Res. 2016 Sep;46(10):951-63
pubmed: 27481650
Pancreatology. 2015 Jan-Feb;15(1):19-24
pubmed: 25524484
J Surg Oncol. 2015 May;111(6):771-5
pubmed: 25556324
JPEN J Parenter Enteral Nutr. 2017 Jun 1;:148607117718494
pubmed: 28654309
World J Gastrointest Oncol. 2019 Jul 15;11(7):527-537
pubmed: 31367272
EBioMedicine. 2019 Nov;49:381-388
pubmed: 31662290
JAMA Oncol. 2018 Mar 08;4(3):e173420
pubmed: 29098284
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
World J Surg. 2019 Sep;43(9):2271-2280
pubmed: 31041559
Surgery. 2015 Jun;157(6):1088-98
pubmed: 25799468
Surgery. 2012 Sep;152(3 Suppl 1):S103-11
pubmed: 22766366
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
JAMA. 2007 Jan 17;297(3):267-77
pubmed: 17227978
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834